Literature DB >> 17547461

Straightforward methodology for the enantioselective synthesis of benzo[a]- and indolo[2,3-a]quinolizidines.

Mercedes Amat1, Maria M M Santos, Oriol Bassas, Núria Llor, Carmen Escolano, Arantxa Gómez-Esqué, Elies Molins, Steven M Allin, Vickie McKee, Joan Bosch.   

Abstract

An enantioselective two-step route to substituted benzo[a]- and indolo[2,3-a]quinolizidines has been developed. It consists of (i) a stereoselective cyclocondensation of a racemic or prochiral delta-oxo(di)ester with either (S)-(3,4-dimethoxyphenyl)alaninol or (S)-tryptophanol in a process involving a dynamic kinetic resolution and/or the differentiation of enantiotopic or diastereotopic ester groups, and (ii) a subsequent stereocontrolled cyclization on the aromatic ring taking advantage of the masked N-acyl iminium ion present in the resulting oxazolopiperidone lactams.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17547461     DOI: 10.1021/jo070539g

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  4 in total

1.  One-step route to tricyclic fused 1,2,3,4-tetrahydroisoquinoline systems via the Castagnoli-Cushman protocol.

Authors:  Aleksandar Pashev; Nikola Burdzhiev; Elena Stanoeva
Journal:  Beilstein J Org Chem       Date:  2020-06-24       Impact factor: 2.883

Review 2.  The Chiral Pool in the Pictet-Spengler Reaction for the Synthesis of β-Carbolines.

Authors:  Renato Dalpozzo
Journal:  Molecules       Date:  2016-05-27       Impact factor: 4.411

3.  Studies on the Enantioselective Synthesis of E-Ethylidene-bearing Spiro[indolizidine-1,3'-oxindole] Alkaloids.

Authors:  Nihan Yayik; Maria Pérez; Elies Molins; Joan Bosch; Mercedes Amat
Journal:  Molecules       Date:  2021-01-15       Impact factor: 4.411

4.  Enantiopure Indolo[2,3-a]quinolizidines: Synthesis and Evaluation as NMDA Receptor Antagonists.

Authors:  Nuno A L Pereira; Francesc X Sureda; Maria Pérez; Mercedes Amat; Maria M M Santos
Journal:  Molecules       Date:  2016-08-06       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.